Top Clinical Trials companies in Taiwan by Price to Book Ratio (P/B)

This ranking features the top 3 Clinical Trials companies in Taiwan ranked by Price to Book Ratio (P/B), averaging a Price to Book Ratio (P/B) of 4.48, for January 15, 2025.

Taiwan

Clinical Trials
Price to Book Ratio (P/B)
#
Name
Price to Book Ratio (P/B)
 Reported Date
Stock Price
Change
 Price (30 days) Country
1
4147.TWO

TaiMed Biologics Inc.

1

4147.TWO

8.44

 Jan. 14, 2025 USD 2.64 -2.78%

Taiwan
2
4174.TWO

OBI Pharma, Inc.

2

4174.TWO

3.58

 Jan. 14, 2025 USD 1.70 1.57%

Taiwan
3
4128.TWO

Microbio Co., Ltd.

3

4128.TWO

1.43

 Jan. 14, 2025 USD 0.93 4.52%

Taiwan
Frequently Asked Questions
  • Which Clinical Trials company in Taiwan has the highest Price to Book Ratio (P/B) ?

    The Clinical Trials company in Taiwan with the highest Price to Book Ratio (P/B) is TaiMed Biologics Inc. (Taipei Exchange: 4147.TWO) at 8.44.

  • Which Clinical Trials company in Taiwan has the lowest Price to Book Ratio (P/B) ?

    The Clinical Trials company in Taiwan with the lowest Price to Book Ratio (P/B) is Microbio Co., Ltd. (Taipei Exchange: 4128.TWO) at 1.43.